Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N.

Pharmacogenomics. 2008 Oct;9(10):1445-58. doi: 10.2217/14622416.9.10.1445.

PMID:
18855533
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT.

Pharmacogenomics. 2008 May;9(5):511-26. doi: 10.2217/14622416.9.5.511.

PMID:
18466099
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.

PMID:
19297219
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium.

Blood. 2010 May 6;115(18):3827-34. doi: 10.1182/blood-2009-12-255992. Epub 2010 Mar 4.

PMID:
20203262
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

New genetic variant that might improve warfarin dose prediction in African Americans.

Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE.

Br J Clin Pharmacol. 2010 Sep;70(3):393-9. doi: 10.1111/j.1365-2125.2010.03709.x.

PMID:
20716240
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.

Shrif NE, Won HH, Lee ST, Park JH, Kim KK, Kim MJ, Kim S, Lee SY, Ki CS, Osman IM, Rhman EA, Ali IA, Idris MN, Kim JW.

Eur J Clin Pharmacol. 2011 Nov;67(11):1119-30. doi: 10.1007/s00228-011-1060-1. Epub 2011 May 18.

PMID:
21590310
[PubMed - indexed for MEDLINE]
7.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

PMID:
19663669
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.

Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Müller CR, Wienker TF, Oldenburg J.

Thromb Haemost. 2005 Oct;94(4):773-9.

PMID:
16270629
[PubMed - indexed for MEDLINE]
9.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
[PubMed - indexed for MEDLINE]
10.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE.

N Engl J Med. 2005 Jun 2;352(22):2285-93.

PMID:
15930419
[PubMed - indexed for MEDLINE]
Free Article
11.

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.

Pharmacogenomics. 2012 Mar;13(4):407-18. doi: 10.2217/pgs.11.164. Epub 2012 Feb 13.

PMID:
22329724
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.

Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE.

Pharmacogenet Genomics. 2005 Oct;15(10):687-91.

PMID:
16141794
[PubMed - indexed for MEDLINE]
13.

Genetic and clinical predictors of warfarin dose requirements in African Americans.

Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA.

Clin Pharmacol Ther. 2010 Apr;87(4):459-64. doi: 10.1038/clpt.2009.223. Epub 2010 Jan 13.

PMID:
20072124
[PubMed - indexed for MEDLINE]
14.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H.

Pharmacogenet Genomics. 2006 Feb;16(2):101-10.

PMID:
16424822
[PubMed - indexed for MEDLINE]
15.

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF.

Clin Pharmacol Ther. 2010 Apr;87(4):445-51. doi: 10.1038/clpt.2009.291. Epub 2010 Mar 3.

PMID:
20200517
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ.

Clin Pharmacol Ther. 2011 Mar;89(3):408-15. doi: 10.1038/clpt.2010.322. Epub 2011 Jan 26.

PMID:
21270790
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
[PubMed - indexed for MEDLINE]
18.

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.

Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA.

Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.

PMID:
23755828
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.

El Din MS, Amin DG, Ragab SB, Ashour EE, Mohamed MH, Mohamed AM.

Int J Lab Hematol. 2012 Oct;34(5):517-24. doi: 10.1111/j.1751-553X.2012.01426.x. Epub 2012 Apr 26.

PMID:
22533669
[PubMed - indexed for MEDLINE]
20.

VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.

Orsi FA, Annichino Bizzacchi JM, de Paula EV, Ozelo MC, Langley MR, Weck KE.

Thromb Res. 2010 Sep;126(3):e206-10. doi: 10.1016/j.thromres.2010.06.008. Epub 2010 Jul 7.

PMID:
20615525
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk